Newsfeeds Archive - Page 4 of 4

1 minute read

Legal
News

Lantern Pharma Announces Issuance Of New Patent That Strengthens Patent Portfolio For Cancer Drug Candidate LP-300

October 20, 7:59 AM

U.S. Patent No. 11,471,431 relates to the use of LP-300 to increase the survival time of patients with cancers overexpressing thioredoxin or glutaredoxin. The patent issuance extends commercial protection for uses of

LTRN

2 minute read

Lantern Pharma to Present Preclinical Data On The Efficacy Of LP-284 For Mantle Cell Lymphoma At The Society Of Hematologic Oncology Annual Meeting September 28

By Benzinga Newsdesk

September 23, 8:51 AM

Lantern Pharma Inc. (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning ("M.L.") platform to

LTRN

56 minute read

Options

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

September 22, 2:17 PM

On Thursday, 1076 companies hit new 52-week lows.

$APE

1 minute read

Earnings

Recap: Lantern Pharma Q2 Earnings

By Benzinga Insights

August 8, 5:15 PM

Lantern Pharma (NASDAQ:LTRN) reported its Q2 earnings results on Monday, August 8, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

LTRN

1 minute read

12 Health Care Stocks Moving In Friday’s Pre-Market Session

By Benzinga Insights

July 15, 8:14 AM

ALLO

1 minute read

Lantern Pharma Gets FDA Clearance for Mid-Stage Lung Cancer Study

By Ragothaman Srinivasan

July 14, 9:31 AM

The Food and Drug Administration (FDA) has announced clearance to Lantern Pharma (NASDAQ: LTRN) to proceed with Phase 2 clinical trial of its investigational new drug LP-300 in combination with chemotherapy for never smoker patients with advanced non-small cell lung cancer (N

LTRN

1 minute read

Lantern Pharma Receives FDA Authorization To Initiate Its Phase 2 Clinical Trial, Harmonic, For LP-300 In Never Smokers With Non-Small Cell Lung Cancer

By Benzinga Newsdesk

July 14, 7:01 AM

The Harmonic™ trial is a Phase 2 multi-center study focused on never smokers with advanced non-small cell lung cancer (NSCLC) and will begin patient enrollment during Q3 2022. In a previous Phase 3

LTRN